Leuprolide
Also referenced as: Lupron
A GnRH agonist with multiple product-specific endocrine suppression indications.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved formulations cover advanced prostate cancer, endometriosis, specified fibroid-associated anemia with iron, and central precocious puberty under distinct label criteria.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GnRH agonist with multiple product-specific endocrine suppression indications.
FDA-approved formulations cover advanced prostate cancer, endometriosis, specified fibroid-associated anemia with iron, and central precocious puberty under distinct label criteria.
Formulations and age groups are not interchangeable; this medicine generally suppresses rather than enhances sex-steroid signalling.
Why It's Being Studied
- Prostate cancer
- Endometriosis
- Central precocious puberty
Mechanism of Action
Sustained GnRH-receptor activation suppresses LH, FSH and gonadal steroids after an initial flare.
Sustained GnRH-receptor activation suppresses LH, FSH and gonadal steroids after an initial flare. Formulations and age groups are not interchangeable; this medicine generally suppresses rather than enhances sex-steroid signalling.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Prostate cancer
- Endometriosis
- Central precocious puberty
- Product-specific approved injections
Evidence Summary
Extensive human evidence supports labeled hormone-sensitive cancer and gynecologic or pediatric uses.
Higher tiers carry more weight. Filled tiers have evidence for Leuprolide; tap to read it.
- Extensive human evidence supports labeled hormone-sensitive cancer and gynecologic or pediatric uses.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Extensive human evidence supports labeled hormone-sensitive cancer and gynecologic or pediatric uses.
Reported Adverse Events in Research
- Tumor flare, bone loss, metabolic or cardiovascular effects and pediatric psychiatric or seizure warnings matter.
Limitations of Current Evidence
- Formulations and age groups are not interchangeable; this medicine generally suppresses rather than enhances sex-steroid signalling.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Leuprolide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Product-specific approved injections | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Leuprolide — prescribing label